Microcosting Study of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Prostate Cancer.

Male Humans Positron Emission Tomography Computed Tomography / methods Prostate Gallium Isotopes Prostatic Neoplasms / diagnostic imaging
Australia computed tomography costs imaging positron emission tomography prostate cancer prostate-specific membrane antigen prostatic neoplasms

Journal

Value in health regional issues
ISSN: 2212-1102
Titre abrégé: Value Health Reg Issues
Pays: United States
ID NLM: 101592642

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 08 02 2022
revised: 16 05 2022
accepted: 15 06 2022
pubmed: 14 8 2022
medline: 9 11 2022
entrez: 13 8 2022
Statut: ppublish

Résumé

Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has emerged as a promising imaging tool in prostate cancer diagnosis. PSMA PET/CT radiotracers are produced in-house (gallium-68, eg, Hospitals and diagnostic facilities currently conducting PSMA PET/CT in Australia in metropolitan and regional areas completed a survey of PSMA PET/CT throughput, radiotracers involved, and the cost of assets, departmental staffing, consumables, and occupancy. Total costs were estimated using a top-down microcosting approach, involving identifying all relevant cost components and valuing each component for the average patient, and a gross costing approach, involving apportioning cost components at an aggregated level. Data were collected from 8 facilities. The most common radiotracer used was This study provides a detailed and accurate estimation of the cost of PSMA PET/CT in Australia. These costs can be used as a benchmark to identify potential efficiencies and help policy makers set the appropriate reimbursement rate for this procedure. The use of data from facilities using different radiotracers in metropolitan and regional areas and with different throughput increases the generalizability of the results, especially in countries with similar health systems.

Identifiants

DOI: 10.1016/j.vhri.2022.06.005 PMID: 35963186
pubmed: 35963186
pii: S2212-1099(22)00130-3
doi: 10.1016/j.vhri.2022.06.005
pii:
doi:

Substances chimiques

gallium 68 PSMA-11 0
Gallium Isotopes 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17-22

Informations de copyright

Copyright © 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Auteurs

Bonny Parkinson (B)

Macquarie University Centre for the Health Economy, Macquarie University, Sydney, NSW, Australia; Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia; Macquarie Business School, Macquarie University, Sydney, NSW, Australia. Electronic address: bonny.parkinson@mq.edu.au.

Rajan Sharma (R)

Macquarie University Centre for the Health Economy, Macquarie University, Sydney, NSW, Australia; Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia; Macquarie Business School, Macquarie University, Sydney, NSW, Australia.

Varinder Jeet (V)

Macquarie University Centre for the Health Economy, Macquarie University, Sydney, NSW, Australia; Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia; Macquarie Business School, Macquarie University, Sydney, NSW, Australia.

Rachel Song (R)

Macquarie University Centre for the Health Economy, Macquarie University, Sydney, NSW, Australia; Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia; Macquarie Business School, Macquarie University, Sydney, NSW, Australia.

Martin Hoyle (M)

Macquarie University Centre for the Health Economy, Macquarie University, Sydney, NSW, Australia; Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia; Macquarie Business School, Macquarie University, Sydney, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Microcosting Study of Prostate-Specific...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › Microcosting Study of Prostate-Specific...
questionsmedicales.fr › Tissus › Glandes exocrines › Prostate › Microcosting Study of Prostate-Specific...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Métaux lourds › Gallium › Isotopes du gallium › Microcosting Study of Prostate-Specific...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Microcosting Study of Prostate-Specific...